top of page

Malaysia’s - DRAFT GUIDANCE DOCUMENT LICENSING FOR ESTABLISHMENT

Writer's picture: Sharan MuruganSharan Murugan

Malaysia’s Medical Device Authority (MDA) & Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) has updated guidance updates respectively this week.


LICENSING FOR ESTABLISHMENT

Medical Device Authority (MDA) is seeking input on its plans to revise its guidance on obtaining a license to import, export or place products on the market.


The draft includes additional definitions and new requirements relating to postmarket responsibilities.


This guidance document applies to establishments as defined under Section 2 of the Medical Device Act 2012 (Act 737).


This guidance document covers establishment licensing procedures; licensing for multiple roles; obligations of the establishment; amendment application of establishment license; and renewal of establishment license.


Click on this LINK to know more about the types of licenses, the application process, etc.


UPDATES TO CHANGES TO MANUFACTURING FACILITIES


The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia has updated its position on changes to foreign manufacturing facilities and plants making sterile products.


Click on this LINK to know more about the Type III changes to the location of facilities outside of the countr and a simplified description of Type IV changes.


Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page